skip to Main Content

Promising Glioma Results

Forma Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced recently that the company’s investigational IDH1m inhibitor, olutasidenib, demonstrated a preliminary disease control rate of 50% in heavily pre-treated patients with predominantly enhancing, recurrent mIDH1…   Read More

Back To Top